Nymox Pharmaceutical Co. (NASDAQ:NYMX) Director James George Robinson Purchases 8,000 Shares

Share on StockTwits

Nymox Pharmaceutical Co. (NASDAQ:NYMX) Director James George Robinson purchased 8,000 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was purchased at an average price of $3.48 per share, for a total transaction of $27,840.00. Following the completion of the transaction, the director now directly owns 3,136,550 shares in the company, valued at $10,915,194. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

James George Robinson also recently made the following trade(s):

  • On Monday, March 26th, James George Robinson purchased 8,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $3.93 per share, for a total transaction of $31,440.00.
  • On Tuesday, March 20th, James George Robinson bought 8,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $4.02 per share, with a total value of $32,160.00.
  • On Thursday, March 15th, James George Robinson bought 8,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.58 per share, with a total value of $28,640.00.
  • On Wednesday, February 21st, James George Robinson bought 6,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.23 per share, with a total value of $19,380.00.
  • On Friday, February 16th, James George Robinson bought 7,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.27 per share, with a total value of $22,890.00.
  • On Monday, February 12th, James George Robinson bought 8,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.27 per share, with a total value of $26,160.00.
  • On Thursday, February 8th, James George Robinson bought 10,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.37 per share, with a total value of $33,700.00.
  • On Friday, February 2nd, James George Robinson bought 5,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.47 per share, with a total value of $17,350.00.
  • On Thursday, January 18th, James George Robinson bought 3,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average cost of $3.14 per share, with a total value of $9,420.00.

NASDAQ NYMX opened at $4.04 on Friday. Nymox Pharmaceutical Co. has a 52-week low of $3.00 and a 52-week high of $5.10. The company has a debt-to-equity ratio of 61.64, a current ratio of 1.44 and a quick ratio of 1.42.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC bought a new stake in Nymox Pharmaceutical during the 2nd quarter worth approximately $329,000. Wedbush Securities Inc. grew its stake in shares of Nymox Pharmaceutical by 6.7% during the 4th quarter. Wedbush Securities Inc. now owns 277,177 shares of the biopharmaceutical company’s stock worth $915,000 after acquiring an additional 17,485 shares in the last quarter. Teachers Advisors LLC bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth approximately $218,000. Schwab Charles Investment Management Inc. bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth approximately $222,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth approximately $117,000. 6.42% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Nymox Pharmaceutical Co. (NASDAQ:NYMX) Director James George Robinson Purchases 8,000 Shares” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://baseballnewssource.com/2018/04/07/nymox-pharmaceutical-co-nymx-director-purchases-27840-00-in-stock/2038221.html.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.